Welcome to the first issue of TLDR Biotech!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals & Labels

X4 Pharmaceuticals - Rare disease FDA approval for WHIM syndrome
Small molecule - Read more

Abbott - FDA approval for dissolving arterial stents, “groundbreaking”
Medical device - Read more

THE GOOD
Clinical Trials

AstraZeneca, Daiichi Sankyo - Phase 3 success, breast cancer label expansion attempt
ADC (Enhertu) - Read more

Merck & Co. - hitting their STRIDE with Phase 3 positive pneumococcal vaccine data
Conjugate vaccine - Read more

Prime Medicine - Prime-time for prime-editing as FDA gives go-ahead for first clinical trial
Prime Editing, Gene Editing, CRISPR - Read more

AriBio - EMA approves Phase 3 Alzheimer’s trial
Small molecule - Read more

THE GOOD
Expansions

Merck KGaA - €300M for new HQ-based research center in Darmstadt, Germany - Read more

THE GOOD
Fundraises

4P Pharma - €15M Second Funding raise
Clinical-stage, “startup studio model” - Read more

Locate Bio - £9.2M raise
Orthobiologics, drug delivery - Read more

THE GOOD
Mergers & Acquisitions, Business Development

Ono Pharmaceuticals buys Deciphera Pharmaceuticals
$2.4B - all cash deal @$25.60/share, 75% premium
Small molecule, cancer, market access - Read more

Mosaic ImmunoEngineering buys clinical program from Oncotelic
Deal details not disclosed
Cancer, immunotherapy combos - Read more

THE GOOD
Partnerships

Bristol Myers Squibb with Repertoire Immune Medicine, vaccine development pact
$65M upfront, $1.8B milestones
mRNA vaccines, autoimmune - Read more

Celltrion with Express Scripts, ZYMFENTRA “Preferred Brand Access”
mAb, biosimilar - Read more

THE GOOD
Product Launches

Merck KGaA with Huma Therapeutics, cancer resource app
Bladder cancer - Read more

THE GOOD
Regulatory

FDA moves to regulate laboratory testing - Read more

Novo Nordisk gets FDA adcomm for weekly insulin
Insulin analogue - Read more

THE BAD
Clinical Trials

Addex Therapeutics Phase 2 epilepsy fail
Small molecule - Read more

THE BAD
Mergers & Acquisitions, Business Development

BioMarin courts divestiture as Roctavian sales struggle
Gene therapy - Read more

THE UGLY
Geopolitics

WuXi AppTec makes move to regain trust
CDMO, CRO, Biosecure Act - Read more

THE UGLY
Lawsuits

J&J, Bristol Myers Squibb IRA suit gets boot by federal judge
Inflation Reduction Act - Read more

THE UGLY
Opinions

Pharma industry reputation stumbles post-pandemic
Patient surveys - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️